Table 1.
Clinical and laboratory characteristics of 22 patients with Waldenström macroglobulinemia.
| Characteristic | Number of patients/total | (%) |
|---|---|---|
| Age > 65 years | 11/22 | 50 |
| Male sex | 17/22 | 77 |
| Performance status* | ||
| 0 to 2 | 20/22 | 91 |
| 3 or 4 | 2/22 | 9 |
| B symptoms | 12/22 | 55 |
| Hyperviscosity | 8/22 | 36 |
| Cryoglobulinemia | 3/10 | 30 |
| Hepatomegaly | 7/22 | 32 |
| Splenomegaly | 10/22 | 45 |
| Lymphadenopathy | 16/22 | 73 |
| Peripheral neuropathy | 2/22 | 9 |
| Multiple osteolytic lesions | 2/22 | 9 |
| Hemoglobin ≤11.5 g/dL | 20/22 | 91 |
| Platelet < 100 × 109/L | 6/22 | 27 |
| Monoclonal protein type | ||
| IgMκ | 18/22 | 82 |
| IgMλ | 4/22 | 18 |
Ig: immunoglobulin.
*Performance status is according to Eastern Cooperative Oncology Group (ECOG) score as follows: 0: without symptoms; 1: mild symptoms not requiring treatment; 2: symptoms requiring some treatment; 3: disabling symptoms but allowing ambulation for >50% of the day; 4: ambulation < 50% of the day.